Abstract:The observation that SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) predisposes patients to pulmonary immunothrombosis and venous thromboembolism (VTE), and furthermore, that the risk of VTE is directly proportional to the severity of coronavirus disease 2019 (COVID-19) disease has been recognized since early in the pandemic.[1] Guidelines recommend the use of prophylactic anticoagulation in hospitalized patients with COVID-19,[2] [3] [4] yet despite this, trials report a VTE incidence of 6 to 10% with prophylactic and 4 to 8% with treatment-dose anticoagulation.[5] [6] Amongst critically ill patients with COVID-19, 28 to 46% of patients may experience VTE.[7] [8] [9] The mechanism of thrombosis in patients with COVID-19 involves an excessive inflammatory response, which is manifested through an endotheliopathy, enhanced platelet activation and coagulation, and reduced endogenous fibrinolysis.[7] [10] [11] Early on in the pandemic, it was recognized that common markers of coagulation, namely D-dimer, fibrinogen, prothrombin time, as well as platelet count, could be used to assess the severity of COVID-19 and help triage patients for admission, guide prognosis, and assess the risk of VTE.[12] Over time, other markers of thrombosis risk have emerged, which can guide prognosis and potentially guide therapy.[7] [13] [14] [15] [16] These include, inter alia , interleukin (IL)-6, von Willebrand factor (vWF) antigen, or the ratio of vWF antigen to ADAMTS13, as well as markers of platelet activation, hypofibrinolysis, and neutrophil extracellular traps. In this issue of Thrombosis and Haemostasis, Li et al provide further insight into biomarkers of thrombosis in patients with COVID-19.[17] In a retrospective analysis using two-sample Mendelian randomization (MR), they evaluated the relationship between 20 biomarkers in patients with COVID-19 of varying severity, including nonhospitalized, hospitalized, and critically ill patients. Data from genome-wide association studies (GWAS) were analyzed from 38,984 patients from 37 studies with COVID-19 and from a GWAS meta-analysis of 9,986 hospitalized COVID-19 patients from 22 cohorts and from 5,101 and 4,792 critically ill COVID-19 patients from 15 and 14 studies, respectively. The main finding was that patients with COVID-19 had lower levels of tissue factor pathway inhibitor (TFPI) and lower levels of IL-1 receptor type 1 (IL-1R1). Additionally, patients with COVID-19 exhibited a trend toward lower levels of multiple coagulation factor deficiency protein 2 and increased C–C motif chemokine 3. Furthermore, patients hospitalized with COVID-19 had lower levels of plasminogen activator, tissue type plasminogen activator, and P-selectin glycoprotein ligand 1. Finally, the authors confirmed earlier findings that critically ill patients had higher mean platelet volume and lower platelet count. The authors provide information from a very large dataset that appears to yield new insight into the mechanism of thrombosis and inflammation in patients with COVID-19. TFPI is the key inhibitor of the tissue factor-induced coagulation pathway. Findings in animal models indicate a role of TFPI in attenuating arterial thrombus formation,[18] and TFPI has also been implicated VTE including in patients with cancer.[18] [19] In animal models of sepsis, coagulation in the lung was associated with decreased TFPI in the lung endothelium.[20] However, prior studies evaluating TFPI in COVID-19 patients have shown conflicting results. Some small studies showed significantly elevated TFPI levels in patients with COVID-19,[21] which did not relate to disease severity, while others found reduced TFPI in patients with moderate to severe disease.[22] Other studies have found increased TFPI associated with the severity of COVID-19.[23] [24] Likewise, TFPI has been directly correlated with D-dimer levels, which were associated with high mortality,[21] while others showed an inverse correlation of TFPI with D-dimer levels.[25] The finding of lower TFPI levels in COVID-19 patients by Li et al supports the possible contribution of TF pathway activation to COVID-19 coagulopathy.[22] Although approximately 10% of circulating TFPI is stored in platelets, the largest pool of TFPI exists bound to endothelial surfaces. Therefore, in light of the endotheliopathy associated with COVID-19, one would expect an increase in TFPI levels in those with severe disease. In addition, heparin infusion has been shown to displace endothelial TFPI resulting in a two- to fourfold increase in circulating TFPI levels,[26] and may explain the increased plasma TFPI reported in some studies in COVID-19 patients.[21] [24] However, the reduced TFPI shown in the present study indicates that a procoagulant phenotype, withou -Abstract Truncated-

Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases

Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications

Expression of Tissue Factor and Platelet/Leukocyte Markers on Extracellular Vesicles Reflect Platelet-Leukocyte Interaction in Severe COVID-19

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19

Head-to-Head Comparison of Tissue Factor-Dependent Procoagulant Potential of Small and Large Extracellular Vesicles in Healthy Subjects and in Patients with SARS-CoV-2 Infection

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation

Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease

[Tissue factors and venous thromboembolism in cancer patients].

In Covid-19 Infection, Plasma Extracellular Vesicle Tissue Factor Activity Does Not Correlate with D-Dimer Levels

Relationship Between Plasma Tissue Factor and Pathological Features of Lung Cancer

Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection

Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19

Coagulation abnormalities in SARS-CoV-2 infection: overexpression tissue factor

Coagulation potential and the integrated omics of extracellular vesicles from COVID-19 positive patient plasma

Extracellular Vesicles Linking Inflammation, Cancer and Thrombotic Risks

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

Characterization of extracellular vesicles from patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and assessment of their coagulation potential

Tissue Factor in Tumor Microenvironment: a Systematic Review

Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent Endothelial Cells via Protease-Activated Receptor-1

Procoagulant Activity of Umbilical Cord-Derived Mesenchymal Stromal Cells’ Extracellular Vesicles (MSC-EVs)

Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology